The small molecule TGF-β signaling inhibitor SM16 synergizes with agonistic OX40 antibody to suppress established mammary tumors and reduce spontaneous metastasis

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Cancer Immunology and Immunotherapy

• Publication date

  2012-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s00262-011-1119-yPMID 21971588PMCID PMC3595193
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Use of anti-cancer drugs, mitocans, to enhance the immune responses against tumors.

  2013cited by this paper
• A systems level strategy for analyzing the cell death network: implication in exploring the apoptosis/autophagy connection

  2010cited by this paper
• Toll-Like Receptors, Tissue Injury, and Tumourigenesis

  2010cited by this paper
• Life and death partners: apoptosis, autophagy and the cross-talk between them

  2009cited by this paper
• An orally active small molecule TGF-beta receptor I antagonist inhibits the growth of metastatic murine breast cancer.

  2009cited by this paper
• The paradox of autophagy and its implication in cancer etiology and therapy

  2009cited by this paper
• Costimulation as a platform for the development of vaccines: a peptide-based vaccine containing a novel form of 4-1BB ligand eradicates established tumors.

  2009cited by this paper
• CD137 Costimulation of CD8+ T Cells Confers Resistance to Suppression by Virus-Induced Regulatory T Cells1

  2008cited by this paper
• OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor.

  2008cited by this paper
• An anti-transforming growth factor beta antibody suppresses metastasis via cooperative effects on multiple cell compartments.

  2008cited by this paper
• Transforming Growth Factor-β Receptor Blockade Augments the Effectiveness of Adoptive T-Cell Therapy of Established Solid Cancers

  2008cited by this paper
• OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection

  2008cited by this paper
• A novel small-molecule inhibitor of transforming growth factor beta type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection.

  2007cited by this paper
• OX40 costimulation turns off Foxp3+ Tregs.

  2007cited by this paper
• A Novel Small-Molecule Inhibitor of Transforming Growth Factor β Type I Receptor Kinase (SM16) Inhibits Murine Mesothelioma Tumor Growth In vivo and Prevents Tumor Recurrence after Surgical Resection

  2007cited by this paper
• Functional characterization of OX40 expressed on human CD8+ T cells.

  2006cited by this paper
• OX40 (CD134) engagement drives differentiationof CD4+ T cells to effector cells

  2006cited by this paper
• Triggering of OX40 (CD134) on CD4(+)CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR.

  2005cited by this paper
• Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death

  2005cited by this paper
• Indomethacin modulation of Adriamycin-induced effects on multiple cytolytic effector functions

  2005cited by this paper
• Trastuzumab: updates and future issues

  2005cited by this paper
• Trastuzumab-based combination therapy for breast cancer

  2004cited by this paper
• The costimulation-regulated duration of PKB activation controls T cell longevity

  2004cited by this paper
• SD-208, a Novel Transforming Growth Factor β Receptor I Kinase Inhibitor, Inhibits Growth and Invasiveness and Enhances Immunogenicity of Murine and Human Glioma Cells In vitro and In vivo

  2004cited by this paper
• Distinct Roles for the OX40-OX40 Ligand Interaction in Regulatory and Nonregulatory T Cells1

  2004cited by this paper
• Transforming growth factor beta inhibits the antigen-presenting functions and antitumor activity of dendritic cell vaccines.

  2003cited by this paper
• Co-stimulatory members of the TNFR family: keys to effective T-cell immunity?

  2003cited by this paper
• Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells

  2003cited by this paper
• Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases.

  2002cited by this paper
• Immune-Mediated Eradication of Tumors through the Blockade of Transforming Growth Factor-beta Signaling in T Cells

  2002cited by this paper
• Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines.

  2002cited by this paper
• Expression and costimulatory effects of the TNF receptor superfamily members CD134 (OX40) and CD137 (4‐1BB), and their role in the generation of anti‐tumor immune responses

  2002cited by this paper
• Expression and function of 4-1BB and 4-1BB ligand on murine dendritic cells.

  2002cited by this paper
• Blockade of TGF-β inhibits mammary tumor cell viability, migration, and metastases

  2002cited by this paper
• Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors.

  2002cited by this paper
• OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells.

  2001cited by this paper
• Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T cells

  2001cited by this paper
• Induction of Anti-Mammary Cancer Immunity by Engaging the OX-40 Receptor in Vivo

  2001cited by this paper
• Mechanism of action of trastuzumab and scientific update.

  2001influential reference
• Abrogation of TGFβ Signaling in T Cells Leads to Spontaneous T Cell Differentiation and Autoimmune Disease

  2000cited by this paper
• Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth.

  2000cited by this paper
• Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets

  2000cited by this paper
• New approaches to antibody therapy

  2000cited by this paper
• Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease.

  2000cited by this paper
• Engagement of the OX-40 Receptor In Vivo Enhances Antitumor Immunity1

  2000cited by this paper
• Elevated serum levels of transforming growth factor-beta1 in patients with colorectal carcinoma: its association with tumor progression and its significant decrease after curative surgical resection.

  1999cited by this paper
• Tumor-associated transforming growth factor-beta and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients.

  1999cited by this paper
• Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses.

  1998cited by this paper
• TGFbeta signaling is necessary for carcinoma cell invasiveness and metastasis.

  1998cited by this paper
• Elevated plasma levels of transforming growth factor (TGF)-beta1 and TGF-beta2 in patients with disseminated malignant melanoma.

  1998cited by this paper
• Elevated Plasma Transforming Growth Factor-β1 Levels in Breast Cancer Patients Decrease After Surgical Removal of the Tumor

  1995cited by this paper
• Transforming growth factor beta 1 in ductal carcinoma in situ and invasive carcinomas of the breast.

  1992cited by this paper
• Immunohistochemical staining for transforming growth factor beta 1 associates with disease progression in human breast cancer.

  1992cited by this paper
• Heterogeneity of tumor cells from a single mouse mammary tumor.

  1978cited by this paper
• Accurate identification of experimental pulmonary metastases.

  1966cited by this paper

• OX40/OX40L: a new target for tumor immunotherapy and its clinical research progress

  2026cites this paper
• OX40 signaling in cancer immunotherapy: mechanisms of action, translational applications, and therapeutic perspectives.

  2026cites this paper
• One step further in targeting acute leukemia by combining antibody-based immunotherapies and small molecule inhibitors

  2025cites this paper
• Harnessing synergistic effects of MMP-2 Inhibition and bFGF to simultaneously preserve and vascularize cardiac extracellular matrix after myocardial infarction

  2024cites this paper
• Multifunctional Nanovaccine Sensitizes Breast Cancer to Immune Checkpoint Therapy

  2024cites this paper
• MHC class I upregulation contributes to the therapeutic response to radiotherapy in combination with anti-PD-L1/anti-TGF-β in squamous cell carcinomas with enhanced CD8 T cell memory-driven response.

  2024cites this paper
• Mechanism insights and therapeutic intervention of tumor metastasis: latest developments and perspectives

  2024cites this paper
• Intratumoral immunotherapy with mRNAs encoding chimeric protein constructs encompassing IL-12, CD137 agonists, and TGF-β antagonists

  2023cites this paper
• TGF-β signaling pathway: Therapeutic targeting and potential for anti-cancer immunity.

  2023cites this paper
• Immunoregulatory signal networks and tumor immune evasion mechanisms: insights into therapeutic targets and agents in clinical development.

  2022cites this paper
• Targeting Epithelial-to-Mesenchymal Transition for Breast Cancer Stem Cells Therapeutics

  2021cites this paper
• Targeting integrin αvβ3 with indomethacin inhibits patient‐derived xenograft tumour growth and recurrence in oesophageal squamous cell carcinoma

  2021cites this paper
• Directing T-Cell Immune Responses for Cancer Vaccination and Immunotherapy

  2021cites this paper
• TGF-beta signaling in cancer radiotherapy.

  2021cites this paper
• Reprogramming the tumour microenvironment by radiotherapy: implications for radiotherapy and immunotherapy combinations

  2020cites this paper
• Emerging immunotherapies for metastasis

  2020cites this paper
• Immune Checkpoint Blockade in Gastrointestinal Cancers: The Current Status and Emerging Paradigms

  2020cites this paper
• TGFβ suppresses CD8+ T cell expression of CXCR3 and tumor trafficking

  2020cites this paper
• Effects of Radiation on the Tumor Microenvironment.

  2020cites this paper
• Influence of antigen density and immunosuppressive factors on tumor-targeted costimulation with antibody-fusion proteins and bispecific antibody-mediated T cell response

  2020cites this paper
• T-cell agonists in cancer immunotherapy

  2020cites this paper
• Nanomedicines as Multifunctional Modulators of Melanoma Immune Microenvironment

  2020cites this paper
• Review: Targeting the Transforming Growth Factor-Beta Pathway in Ovarian Cancer

  2019cites this paper
• TGF-β-Mediated Epithelial-Mesenchymal Transition and Cancer Metastasis

  2019cites this paper
• Blockade of TGF-β signaling: a potential target for cancer immunotherapy?

  2019cites this paper
• Combination Immunotherapy Strategies in Breast Cancer

  2019cites this paper
• Immunological Treatment in Gastrointestinal Cancers

  2019cites this paper
• TNFSF4 (OX40L) expression and survival in locally advanced and metastatic melanoma

  2019cites this paper
• Therapeutic targeting of immune checkpoints with small molecule inhibitors.

  2019cites this paper
• Blockade of TGF-β signaling to enhance the antitumor response is accompanied by dysregulation of the functional activity of CD4+CD25+Foxp3+ and CD4+CD25−Foxp3+ T cells

  2019cites this paper
• Oxidative Stress and Cancer Development: Are Noncoding RNAs the Missing Links?

  2019cites this paper
• CD73 expression on effector T cells sustained by TGF-β facilitates tumor resistance to anti-4-1BB/CD137 therapy

  2019cites this paper
• Bone Metastasis of Breast Cancer.

  2019cites this paper
• TGF-β in T Cell Biology: Implications for Cancer Immunotherapy

  2018cites this paper
• Targeting small molecule drugs to T cells with antibody-directed cell-penetrating gold nanoparticles.

  2018cites this paper
• Understanding the Progression of Bone Metastases to Identify Novel Therapeutic Targets

  2018cites this paper
• Tumor-targeted costimulation with antibody-fusion proteins improves bispecific antibody-mediated immune response in presence of immunosuppressive factors

  2017cites this paper
• Targeting TGF-β Signaling in Cancer.

  2017cites this paper
• Design and synthesis of multivalent glycoconjugates for anti-cancer immunotherapy

  2017cites this paper
• Enhancing Adoptive Cell Therapy of Cancer through Targeted Delivery of Small-Molecule Immunomodulators to Internalizing or Noninternalizing Receptors.

  2017cites this paper
• Targeting TGF-β Signaling for Therapeutic Gain.

  2017cites this paper
• Parallel Aspects of the Microenvironment in Cancer and Autoimmune Disease

  2016cites this paper
• Clinical significance of tumor-infiltrating lymphocytes in breast cancer

  2016cites this paper
• The Marine-Derived Oligosaccharide Sulfate MS80, a Novel Transforming Growth Factor β1 Inhibitor, Reverses Epithelial Mesenchymal Transition Induced by Transforming Growth Factor-β1 and Suppresses Tumor Metastasis

  2016influential citation
• Tumor immune remodeling by TGFβ inhibition improves the efficacy of radiation therapy

  2015cites this paper
• Targeting the TGFβ pathway for cancer therapy.

  2015cites this paper
• TNF superfamily protein-protein interactions: feasibility of small- molecule modulation.

  2015cites this paper
• Tissue invasion and metastasis: Molecular, biological and clinical perspectives.

  2015cites this paper
• STAT3 Signaling Is Required for Optimal Regression of Large Established Tumors in Mice Treated with Anti-OX40 and TGFβ Receptor Blockade

  2015cites this paper
• The New Era of Cancer Immunotherapy: Manipulating T-Cell Activity to Overcome Malignancy.

  2015cites this paper
• TGF-β blockade depletes T regulatory cells from metastatic pancreatic tumors in a vaccine dependent manner

  2015cites this paper
• Why has active immunotherapy not worked in lung cancer?

  2015cites this paper
• Therapeutic vaccines for cancer: an overview of clinical trials

  2014cites this paper
• TGF b Inhibition Prior to Hypofractionated Radiation Enhances Ef fi cacy in Preclinical Models

  2014cites this paper
• Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy

  2014cites this paper
• efficacy in preclinical models inhibition prior to hypofractionated radiation enhances β TGF

  2014cites this paper
• TGFβ Inhibition Prior to Hypofractionated Radiation Enhances Efficacy in Preclinical Models

  2014cites this paper
• TGF-beta signaling in cancer treatment.

  2014cites this paper
• The Impact of the Myeloid Response to Radiation Therapy

  2013cites this paper
• Bone Metastasis of Breast Cancer.

  2013cites this paper
• The Current Status of Human Anti-Cancer Vaccines

  2013cites this paper
• The roles of TGFβ in the tumour microenvironment

  2013cites this paper
• Effects of alterations to the tumor microenvironment driven by transforming growth factor beta on tumor progression

  2013cites this paper
• The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy.

  2013cites this paper
• Overlapping activities of TGF-β and Hedgehog signaling in cancer: therapeutic targets for cancer treatment.

  2013cites this paper
• Screening of circulating TGF-β levels and its clinicopathological significance in human breast cancer.

  2013cites this paper
• The role of CD4[superscript +]T cells during adoptive and active-specific cancer immunotherapy

  2012cites this paper
• Identification of a novel human CD4[superscript +] T cell population and overcoming the immunosuppressive environment in large established tumors

  2012cites this paper
• A comparison of epithelial-to-mesenchymal transition and re-epithelialization.

  2012cites this paper